Matinas BioPharma Holdings, Inc. (MTNB)
| Market Cap | 235.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.54M |
| Shares Out | 216.25M |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 903,186 |
| Open | 1.07 |
| Previous Close | 1.09 |
| Day's Range | 1.04 - 1.13 |
| 52-Week Range | 0.67 - 2.22 |
| Beta | 2.19 |
| Analysts | Buy |
| Price Target | 2.75 (+152.3%) |
| Earnings Date | Nov 8, 2021 |
About MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for MTNB stock is "Buy." The 12-month stock price forecast is 2.75, which is an increase of 152.29% from the latest price.
News
Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference
BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...
5 Penny Stocks To Buy According To Analysts With Targets Up To 156%
Penny stocks to buy right now according to analysts. The post 5 Penny Stocks To Buy According To Analysts With Targets Up To 156% appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f...
Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recomm...
Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Matinas BioPharma Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best Ideas Series
BEDMINSTER, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...
Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
– Phase 1 study of oral amikacin in healthy volunteers expected to complete in Q1 2022 – – Phase 1 study of oral amikacin in healthy volunteers expected to complete in Q1 2022 –
Matinas Biopharma Holdings, Inc. (MTNB) Upgraded to Buy: Here's What You Should Know
Matinas Biopharma Holdings, Inc. (MTNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
5 Penny Stocks to Watch That Exploded Today, What You Need to Know
These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks to ...
Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee t...
– Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly –
Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference
BEDMINSTER, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview at ...
Matinas BioPharma Stock Jumps After Meningitis Candidate Data
Matinas BioPharma Holdings Inc (NYSE: MTNB) has announced positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis. The study is s...
Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatme...
– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20 –
Matinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections
Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for th...
Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second ...
Matinas BioPharma to Participate in BTIG Virtual Biotechnology Conference
BEDMINSTER, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate i...
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on Augu...
BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...
Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts
Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -67.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for th...
Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
– Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from se...
Matinas BioPharma Hldgs's Earnings: A Preview
Matinas BioPharma Hldgs (AMEX:MTNB) announces its next round of earnings this Monday, May 10. Here is Benzinga's everything-that-matters guide for this Monday's Q1 earnings announcement.
Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
BEDMINSTER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate ...
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 1...
BEDMINSTER, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of cri...
Matinas BioPharma to Present at the Needham Healthcare Conference
BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Co...